Tuesday, June 1, 2021 Daily Archives

Single-Use Systems for Storing and Shipping Frozen Drug Materials

Using presterilized, single-use freeze–thaw systems instead of traditional freeze–thaw platforms that include stainless-steel tanks and bottles can help biomanufacturers manage the quality of their drug substances. Single-use assemblies reduce the risk of cross-contamination, simplify dispensing, and decrease the number of manual interventions during freezing, thawing, handling, and shipping. However, implementing a freeze–thaw process requires careful testing of the physical and thermal properties of single-use systems and related aseptic connectors as well as assessment of drug-substance quality and stability. Such evaluation…

Inducible Secretion with ESETEC: The Solution for Difficult-to-Produce Proteins

Deprecated: implode(): Passing glue string after array is deprecated. Swap the parameters in /var/www/wp-content/plugins/wistia-wordpress-oembed-plugin/wistia-anti-mangler.php on line 579

This webcast features: Dr. Marcel Thoen, Head of Global Competence Center for Cell Line Development, Wacker Biotech Escherichia coli is the most popular expression system for all nonglycosylated biopharmaceuticals. However, common challenges include purification of expressed proteins recovered from the periplasm or those needing refolding from inclusion bodies. These constraints have been addressed by the unique secretion E. coli expression system ESETEC (E. coli secretion technology) developed by Wacker Biotech. Through years of experience, Wacker Biotech has observed that secretion…

Tools for Simplifying MSC Expansion, Cryopreservation, and DMSO Removal

Deprecated: implode(): Passing glue string after array is deprecated. Swap the parameters in /var/www/wp-content/plugins/wistia-wordpress-oembed-plugin/wistia-anti-mangler.php on line 579

This webcast features: Hilary Sherman, Senior Scientist, Corning Life Sciences Mesenchymal stem cells (MSCs) are one of the most frequently utilized cell types for cell therapy applications due to their ability to be isolated from several sources and easy adaptability to culture conditions. Bone marrow derived MSCs in particular are commonly studied due to their ease of access and achievable therapeutic dosage. While expanding MSCs to achieve these quantities, there is a risk for heterogeneity-induced quality failures during the manufacturing…

Ins & outs: Apeiron Biologics expands management board

Apeiron Biologics makes high level changes to management and supervisory board. Meanwhile, there are changes at Relief Therapeutics. Sit back, put your feet up, and enjoy BioProcess Insider’s Ins & outs. Up first in this week’s Ins & Outs is Apeiron Biologics, a biotech firm that develops immunotherapies for respiratory diseases and cancer. According to the company, it is expanding its management board and supervisory board to meet the firm’s growth requirements. Romana Gugenberger has been appointed as chief medical and…

Danaher boosts lipid services through PNI acquisition

Danaher will increase its lipid service offerings through the acquisition of Canadian-based technology and solution firm Precision Nanosystems. The deal, of which financials have not been disclosed, sees lipid nanoparticle tech firm Precision Nanosystems (PNI) join Danaher Corporation’s family of life science companies, which include Cytiva and Pall. PNI offers consumables, equipment, and reagents to help manufacture lipid nanoparticles for the delivery of genetic medicines, including messenger RNA (mRNA) therapeutics and vaccines. Through the acquisition, Danaher gains PNI’s GenVoy delivery…